PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

Efgartigimod in Myasthenia Gravis: Peak Benefit Real, Durability and MuSK Data Thin

efgartigimodFcRn antagonistgeneralized myasthenia gravisMuSKAChRsystematic reviewmeta-analysisGRADEcorticosteroid sparingneurology Neurology / Neuropharmacology

Background Information

Efgartigimod shows promise for short-term gMG symptom relief.

Generalized myasthenia gravis (gMG) significantly impacts quality of life and current treatments have limitations. Efgartigimod improved MG-ADL and QMG scores in RCTs with an adverse event rate similar to placebo. While RCTs showed short-term efficacy, real-world data were heterogeneous and indicate a need for cyclical retreatment. Efgartigimod improves gMG symptoms short-term, but long-term benefit needs further study.

📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.

Authors: Ahmed GU, Ramsha F, Kinger S, Shaikh JG, Prejna F, Ritik F, Shabir I, Suhail F, Basit MA, Moiz M, Ali A, Manan A, Samadi A, Raza AA

Citation: Ahmed GU, Ramsha F, Kinger S, et al. Safety and Efficacy of Efgartigimod for Generalized Myasthenia Gravis: A Systematic Review and Meta-Analysis. Brain and behavior. 2026;16(11). doi:10.1002/brb3.71875

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
Thanks for the feedback!
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Founding member rate
$8/month. Cancel anytime.

One subscription unlocks this analysis and every other one we publish, plus Practice Signals, PDF reports, and GRADE evidence grades.

Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.
Or $79/year. Founding members keep this rate for as long as they stay subscribed. Cancel anytime from your Account page.